{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:34Z","timestamp":1792801114191,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K99AG071837"],"award-info":[{"award-number":["K99AG071837"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARFD-21-849349"],"award-info":[{"award-number":["AARFD-21-849349"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Phil and Penny Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute","id":[{"id":"https:\/\/ror.org\/0460vf117","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institutes of Health, United States","award":["U24 AG074855"],"award-info":[{"award-number":["U24 AG074855"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biological Staging for Alzheimer\u2019s disease (AD) in clinically unimpaired (CU) individuals is critical for early detection efforts. In this study, we evaluated whether Core 1 biomarkers (plasma p-tau217 and amyloid-PET) within Biological Stage A, the earliest biological stage of AD, predict progression of downstream biomarkers and cognition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used baseline plasma p-tau217 and amyloid-PET, and longitudinal tau-PET, atrophy, and cognition data from the recently completed Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s (A4) Study. PET data were used to identify participants within AD Biological Stage A (amyloid-PET positive and medial temporal tau-PET negative). Within these Stage A participants, linear mixed effects models were used to examine associations between baseline levels of plasma p-tau217 and amyloid-PET burden with longitudinal regional tau-PET, atrophy, and cognition. We additionally evaluated whether p-tau217 and amyloid-PET burden within this group were associated with higher risk of progression to Biological Stage B+ (tau-PET positive in the medial temporal lobe). In our statistical models, we included covariates for age, sex, and APOE4 carriage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 335 A4 participants with complete biomarker data, 222 were identified as being in Biological Stage A. Among Biological Stage A CU, baseline plasma p-tau217 and amyloid-PET burden were associated with faster tau-PET accumulation and atrophy in AD-relevant regions (mean [SD] follow-up time for tau-PET: 4.2 [2.1] years and MRI: 4.2 [1.9] years), as well as faster cognitive decline (mean [SD] follow-up time for PACC: 5.7 [1.6] years) (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Plasma p-tau217 and amyloid-PET burden were also associated with higher risk of progression to Biological Stage B+.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In CU individuals in the initial stage of AD (Biological Stage A), early changing AD biomarkers provide prognostic information of downstream markers of disease. Evaluation of the utility of these measures in a real-world setting is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The A4 study was submitted for registration to clinicaltrials.gov on December 6th, 2013. The study is registered with ID NCT02008357. Screening and data collection for the study began in April 2014.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02044-1","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:57:04Z","timestamp":1775807824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Continuum of Core 1 biomarkers in preclinical Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Leonardino A.","family":"Digma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly A.","family":"Cody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyan","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Insel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Mormino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"1","key":"2044_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"2044_CR2","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2044_CR3","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, Janelidze S, Li Y, He Y, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2023;29(8):1954\u201363.","journal-title":"Nat Med"},{"issue":"7","key":"2044_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaneurol.2025.1100","volume":"82","author":"A Pichet Binette","year":"2025","unstructured":"Pichet Binette A, Smith R, Salvad\u00f3 G, Tideman P, Glans I, van Westen D, et al. Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease. JAMA Neurol. 2025;82(7):666\u201375.","journal-title":"JAMA Neurol"},{"key":"2044_CR5","unstructured":"Johnson DR, Wiste HJ, Lowe V, Schwarz CG, Knopman DS, Vemuri P et al. Staging Alzheimer\u2019s disease through amyloid and tau PET. Brain. 2025;(awaf346):awaf346."},{"issue":"9","key":"2044_CR6","doi-asserted-by":"publisher","first-page":"e70624","DOI":"10.1002\/alz.70624","volume":"21","author":"L Trudel","year":"2025","unstructured":"Trudel L, Therriault J, Macedo AC, Servaes S, Hosseini SA, Bezgin G, et al. Rates of clinical progression according to biological Alzheimer\u2019s disease stages. Alzheimers Dement. 2025;21(9):e70624.","journal-title":"Alzheimers Dement"},{"key":"2044_CR7","doi-asserted-by":"crossref","unstructured":"Trudel L, Therriault J, Macedo AC, Hosseini SA, Fernandez-Arias J, Chan T et al. Clinical-biological Alzheimer\u2019s disease stage concordance: insights from cohorts and autopsy data. Brain. 2026;awag018.","DOI":"10.1093\/brain\/awag018"},{"issue":"1","key":"2044_CR8","doi-asserted-by":"publisher","first-page":"e71017","DOI":"10.1002\/alz.71017","volume":"22","author":"KA Cody","year":"2026","unstructured":"Cody KA, Soko\u0142owski A, Johns E, Guerra LM, Winer JR, Young CB, et al. Characterizing amyloid and tau positron emission tomography-based stages across the clinical continuum. Alzheimers Dement. 2026;22(1):e71017.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2044_CR9","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","volume":"96","author":"LM van der Kall","year":"2021","unstructured":"van der Kall LM, Truong T, Burnham SC, Dor\u00e9 V, Mulligan RS, Bozinovski S, et al. Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals. Neurology. 2021;96(5):e662\u201370.","journal-title":"Neurology"},{"issue":"12","key":"2044_CR10","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S1474-4422(25)00350-3","volume":"24","author":"CR Jack Jr","year":"2025","unstructured":"Jack CR Jr, Hu M, Wiste HJ, Knopman DS, Vemuri P, Graff-Radford J, et al. Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study. Lancet Neurol. 2025;24(12):1016\u201325.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2044_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14283\/jpad.2024.122","volume":"11","author":"RA Sperling","year":"2024","unstructured":"Sperling RA, Donohue MC, Rissman RA, Johnson KA, Rentz DM, Grill JD, et al. Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: Longitudinal data from the A4 and LEARN Studies. J Prev Alzheimers Dis. 2024;11(4):802\u201313.","journal-title":"J Prev Alzheimers Dis"},{"key":"2044_CR12","doi-asserted-by":"crossref","unstructured":"Petersen KK, Mil\u00e0-Alom\u00e0 M, Li Y, Du L, Xiong C, Tosun D et al. Predicting onset of symptomatic Alzheimer\u2019s disease with plasma p-tau217 clocks. Nat Med. 2026;1\u201310.","DOI":"10.1002\/alz70856_099674"},{"key":"2044_CR13","doi-asserted-by":"crossref","unstructured":"Yakoub Y, Gonzalez-Ortiz F, Ashton NJ, D\u00e9ry C, Strikwerda-Brown C, St-Onge F et al. Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults. Neurology. medRxiv; 2024. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2024.05.09.24307120v1.full.pdf.","DOI":"10.1101\/2024.05.09.24307120"},{"issue":"4","key":"2044_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80(4):360\u20139.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2044_CR15","doi-asserted-by":"publisher","first-page":"e12307","DOI":"10.1002\/dad2.12307","volume":"14","author":"V Dor\u00e9","year":"2022","unstructured":"Dor\u00e9 V, Doecke JD, Saad ZS, Triana-Baltzer G, Slemmon R, Krishnadas N, et al. Plasma p217\u2009+\u2009tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer\u2019s continuum. Alzheimers Dement (Amst). 2022;14(1):e12307.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"2044_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739\u201352.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2044_CR17","doi-asserted-by":"publisher","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis EM, Janelidze S, Cody KA, Langhough R, Du L, Chin NA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 2023;5(2):fcad057.","journal-title":"Brain Commun"},{"issue":"12","key":"2044_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389(12):1096\u2013107.","journal-title":"N Engl J Med"},{"issue":"6","key":"2044_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","volume":"77","author":"RA Sperling","year":"2020","unstructured":"Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735\u201345.","journal-title":"JAMA Neurol"},{"issue":"11","key":"2044_CR20","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.114.153494","volume":"56","author":"AD Joshi","year":"2015","unstructured":"Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD Sr. A semiautomated method for quantification of F 18 Florbetapir PET images. J Nucl Med. 2015;56(11):1736\u201341.","journal-title":"J Nucl Med"},{"issue":"8","key":"2044_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669\u201378.","journal-title":"Lancet Neurol"},{"issue":"12","key":"2044_CR22","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14(12):1565\u201371.","journal-title":"Alzheimers Dement"},{"key":"2044_CR23","unstructured":"Data Details. Available from: https:\/\/habs.mgh.harvard.edu\/researchers\/data-details\/. Cited 28 Dec 2024."},{"issue":"6","key":"2044_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2967\/jnumed.117.200006","volume":"59","author":"S Southekal","year":"2018","unstructured":"Southekal S, Devous MD, Sr, Kennedy I, Navitsky M, Lu M, Joshi AD, et al. Flortaucipir F 18 quantitation using Parametric Estimation of Reference Signal Intensity. J Nucl Med. 2018;59(6):944\u201351.","journal-title":"J Nucl Med"},{"issue":"4","key":"2044_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.neuroimage.2012.02.084","volume":"61","author":"M Reuter","year":"2012","unstructured":"Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. NeuroImage. 2012;61(4):1402\u201318.","journal-title":"NeuroImage"},{"key":"2044_CR26","doi-asserted-by":"publisher","unstructured":"Young C, Sheng J, Winer J, Cody K, Sai I, Carlson M, Younes K, et al. Longitudinal trajectories of divergent cortical tau patterns in preclinical Alzheimer's disease. Brain. 2026:awag113. https:\/\/doi.org\/10.1093\/brain\/awag113.","DOI":"10.1093\/brain\/awag113"},{"issue":"4","key":"2044_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.14283\/jpad.2024.134","volume":"11","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Donohue MC, Langford O, Raman R, Abdel-Latif S, Yaari R, et al. Longitudinal phospho-tau217 predicts amyloid positron emission tomography in Asymptomatic Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2024;11(4):823\u201330.","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"2044_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline: Measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961\u201370.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2044_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamaneurol.2017.0892","volume":"74","author":"ME Farrell","year":"2017","unstructured":"Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR, et al. Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: Evidence for a dose-response relationship. JAMA Neurol. 2017;74(7):830\u20138.","journal-title":"JAMA Neurol"},{"issue":"8","key":"2044_CR30","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/brain\/awy150","volume":"141","author":"M Bilgel","year":"2018","unstructured":"Bilgel M, An Y, Helphrey J, Elkins W, Gomez G, Wong DF, et al. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain. 2018;141(8):2475\u201385.","journal-title":"Brain"},{"issue":"1","key":"2044_CR31","doi-asserted-by":"publisher","first-page":"fcaa007","DOI":"10.1093\/braincomms\/fcaa007","volume":"2","author":"PS Insel","year":"2020","unstructured":"Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid \u03b2 and tau in Alzheimer\u2019s disease: implications for primary prevention. Brain Commun. 2020;2(1):fcaa007.","journal-title":"Brain Commun"},{"issue":"5","key":"2044_CR32","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain. 2018;141(5):1517\u201328.","journal-title":"Brain"},{"issue":"10","key":"2044_CR33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","volume":"79","author":"C Strikwerda-Brown","year":"2022","unstructured":"Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 2022;79(10):975\u201385.","journal-title":"JAMA Neurol"},{"issue":"11","key":"2044_CR34","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137.","journal-title":"Nat Med"},{"issue":"6","key":"2044_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/ana.78003","volume":"98","author":"J Graff-Radford","year":"2025","unstructured":"Graff-Radford J, Syrjanen JA, Vemuri P, Lowe VJ, Schwarz CG, Wiste HJ, et al. Predictive value of plasma biomarkers in tau-PET transitions. Ann Neurol. 2025;98(6):1249\u201360.","journal-title":"Ann Neurol"},{"key":"2044_CR36","unstructured":"Office of the Commissioner. U.S. Food and Drug Administration. FDA. 2025. FDA Clears First Blood Test Used in Diagnosing Alzheimer\u2019s Disease. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease. Cited 20 Aug 2025."},{"issue":"2","key":"2044_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2023;80(2):188\u201399.","journal-title":"JAMA Neurol"},{"issue":"2","key":"2044_CR38","doi-asserted-by":"publisher","first-page":"e14458","DOI":"10.1002\/alz.14458","volume":"21","author":"M Khalafi","year":"2025","unstructured":"Khalafi M, Dartora WJ, McIntire LBJ, Butler TA, Wartchow KM, Hojjati SH, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis. Alzheimers Dement. 2025;21(2):e14458.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2044_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 2022;79(2):149\u201358.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2044_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"issue":"2","key":"2044_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149\u201356.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2044_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JAD-221118","volume":"92","author":"CN Winston","year":"2023","unstructured":"Winston CN, Langford O, Levin N, Raman R, Yarasheski K, West T, et al. Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer\u2019s disease. J Alzheimers Dis. 2023;92(1):95\u2013107.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2044_CR43","doi-asserted-by":"publisher","first-page":"831","DOI":"10.14283\/jpad.2024.124","volume":"11","author":"D Molina-Henry","year":"2024","unstructured":"Molina-Henry D, Langford O, Donohue MC, Raman R, Aisen P, Johnson KA, et al. Relationship between plasma P-Tau217 and amyloid PET in racial and ethnic underrepresented groups (RE-URG) compared with non RE-URG in LEARN and A4. J Prev Alzheimers Dis. 2024;11(4):831\u20137.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"2044_CR44","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/alz.13542","volume":"20","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, et al. Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(2):1214\u201324.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2044_CR45","doi-asserted-by":"publisher","first-page":"fcaf449","DOI":"10.1093\/braincomms\/fcaf449","volume":"7","author":"KA Cody","year":"2025","unstructured":"Cody KA, Langhough RE, Janelidze S, Jonaitis EM, Wilson RE, Christian BT, et al. Characterizing the onset and progression of Alzheimer\u2019s pathologies using amyloid and tau PET imaging and plasma p-tau217. Brain Commun. 2025;7(6):fcaf449.","journal-title":"Brain Commun"},{"issue":"2","key":"2044_CR46","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/alz.13539","volume":"20","author":"PM Cogswell","year":"2024","unstructured":"Cogswell PM, Lundt ES, Therneau TM, Wiste HJ, Graff-Radford J, Algeciras-Schimnich A, et al. Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET. Alzheimers Dement. 2024;20(2):1225\u201338.","journal-title":"Alzheimers Dement"},{"key":"2044_CR47","doi-asserted-by":"crossref","unstructured":"Insel PS, Mattsson-Carlgren N, Langford O, Caruso VM, Leuzy A, Young CB et al. Concurrent longitudinal changes in plasma p-tau217, tau PET, and cognition in preclinical Alzheimer\u2019s disease. medRxiv. 2025. p. 2025.03.25.25324632. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2025.03.25.25324632v1.abstract. Cited 8 Aug 2025.","DOI":"10.1101\/2025.03.25.25324632"},{"issue":"6","key":"2044_CR48","doi-asserted-by":"publisher","first-page":"e214041","DOI":"10.1212\/WNL.0000000000214041","volume":"105","author":"X Wang","year":"2025","unstructured":"Wang X, Ye T, Zhou W, Zhang J, Alzheimer\u2019s Disease Neuroimaging Initiative. Association of distinct initial \u03b2-amyloid levels with tau pathology expansion beyond the entorhinal cortex. Neurology. 2025;105(6):e214041.","journal-title":"Neurology"},{"issue":"1","key":"2044_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-022-00986-w","volume":"14","author":"AJ Weigand","year":"2022","unstructured":"Weigand AJ, Maass A, Eglit GL, Bondi MW. What\u2019s the cut-point? a systematic investigation of tau PET thresholding methods. Alzheimers Res Ther. 2022;14(1):49.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"2044_CR50","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.2967\/jnumed.123.265941","volume":"64","author":"A Gogola","year":"2023","unstructured":"Gogola A, Lopresti BJ, Tudorascu D, Snitz B, Minhas D, Dor\u00e9 V, et al. Biostatistical estimation of tau threshold hallmarks (BETTH) algorithm for human tau PET imaging studies. J Nucl Med. 2023;64(11):1798\u2013805.","journal-title":"J Nucl Med"},{"issue":"11","key":"2044_CR51","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1007\/s00259-023-06280-7","volume":"50","author":"G Quattrini","year":"2023","unstructured":"Quattrini G, Ferrari C, Pievani M, Geviti A, Ribaldi F, Scheffler M, et al. Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2023;50(11):3265\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2044_CR52","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00259-020-05152-8","volume":"48","author":"K Provost","year":"2021","unstructured":"Provost K, Iaccarino L, Soleimani-Meigooni DN, Baker S, Edwards L, Eichenlaub U, et al. Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. Eur J Nucl Med Mol Imaging. 2021;48(7):2259\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2044_CR53","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, et al. The AHEAD 3\u201345 Study: Design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(4):1227\u201333.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2044_CR54","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamaneurol.2022.2442","volume":"79","author":"H Ozlen","year":"2022","unstructured":"Ozlen H, Pichet Binette A, K\u00f6be T, Meyer PF, Gonneaud J, St-Onge F, et al. Spatial extent of amyloid-\u03b2 levels and associations with tau-PET and cognition. JAMA Neurol. 2022;79(10):1025\u201335.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2044_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022;79(3):228\u201343.","journal-title":"JAMA Neurol"},{"issue":"2","key":"2044_CR56","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.neuroimage.2011.07.098","volume":"59","author":"EC Mormino","year":"2012","unstructured":"Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. NeuroImage. 2012;59(2):1152\u201360.","journal-title":"NeuroImage"},{"issue":"6","key":"2044_CR57","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2023.1067","volume":"80","author":"A Leuzy","year":"2023","unstructured":"Leuzy A, Binette AP, Vogel JW, Klein G, Borroni E, Tonietto M, et al. Comparison of group-level and individualized brain regions for measuring change in longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 2023;80(6):614\u201323.","journal-title":"JAMA Neurol"},{"issue":"4","key":"2044_CR58","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/brain\/awac329","volume":"146","author":"C Groot","year":"2023","unstructured":"Groot C, Smith R, Stomrud E, Binette AP, Leuzy A, Wuestefeld A, et al. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Brain. 2023;146(4):1580\u201391.","journal-title":"Brain"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02044-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:45:11Z","timestamp":1781646311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02044-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The A4 study was carried out in concordance with the guidelines from the International Council for Harmonisation Good Clinical Practice. The local ethics review board from each study site approved the study protocol. The study protocol is available as supplementary material in the primary publication for the A4 study [\n                      \n                      ]. Screening and data collection for the study began in April 2014. The study was completed in June 2023. All study participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.A. Digma reports no disclosures; C.B. Young reports no disclosures; J.R. Winer reports no disclosures; K.A. Cody reports no disclosures; K.Younes reports no disclosures; P.S Insel reports no disclosures; R.A. Rissman has received research fundings from the NIA, Alzheimer\u2019s Association, and serves as a consultant for Amydis Inc, Bioivt, Lexeo, Keystone Bio, Allyx, DiamiR, Ionis and PrecisionMed; R. Sperling has received research funding from the NIA, NIH, Alzheimer\u2019s Association, and GHR Foundation, clinical trial funding for public-private partnerships from Eli Lilly and Eisai and Co., and consulting fees from Abbvie, AC Immune, Acumen, Alector, Biohaven, Bristol\u2010Myers Squibb, Genentech, Ionis, Janssen, Merck, Prothena, Roche, Shionogi, and Vaxxinity. E.C. Mormino is a consultant to Neurotrack, Eli Lilly, and Roche and receives funding from the NIH, Simons Foundation, Alzheimer\u2019s Association, and Webb Family Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}